Company Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Xbrane Biopharma AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:59:43 29/04/2024 pm IST			5-day change	1st Jan Change
0.208 ^SEK	-2.58%		-11.49%	-97.92%

22/04	Transcript : Xbrane Biopharma AB - Special Call
18/03	Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index	CI

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Number of employees: 93

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	58	100.0 %	239	100.0 %	+314.33%

SEK in Million	2022	Weight	2023	Weight	Delta
Europe 88.0 %	7	11.6 %	210	88.0 %	+3,034.33%
North America 12.0 %	51	88.4 %	29	12.0 %	-43.61%

Managers	Title	Age	Since
Martin Åmark CEO	Chief Executive Officer	44	01/15/01
Anette Lindqvist DFI	Director of Finance/CFO	63	11/21/11
Dina Jurman CTO	Chief Tech/Sci/R&D Officer	42	09/17/09
David Vikström CTO	Chief Tech/Sci/R&D Officer	47	01/14/01
Siavash Bashiri COO	Chief Operating Officer	41	01/15/01
Nina Ivers HRO	Human Resources Officer	54	16/20/16
Xiaoli Hu PRN	Corporate Officer/Principal	42	01/20/01
Maria Edebrink LAW	General Counsel	55	01/19/01

Members of the board	Title	Age	Since
Karin Helena Johansson Wingstrand BRD	Director/Board Member	67	01/15/01
Kjell Rudolf Peter Edman BRD	Director/Board Member	70	01/15/01
Mats Johan Peter Thorén BRD	Director/Board Member	53	01/20/01
Eva Nilsagård BRD	Director/Board Member	60	16/19/16
Ivan Cohen-Tanugi BRD	Director/Board Member	-	16/19/16
Kirsti Gjellan BRD	Director/Board Member	61	05/22/05
Anders Lennart Tullgren CHM	Chairman	63	03/18/03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,520,328,564	1,357,063,187 ( 89.26 %)	0	89.26 %

Name	Equities	%	Valuation
NORDNET AB 4.728 %	71,877,720	4.728 %	2 M kr
Bengt Goran Westman 1.842 %	28,005,559	1.842 %	789 757 kr
Nidda Topco SARL 0.9115 %	13,857,576	0.9115 %	390 784 kr
Swedbank Robur Fonder AB 0.8557 %	13,009,991	0.8557 %	366 882 kr
Futur Pension Försäkringsaktiebolag 0.8122 %	12,348,316	0.8122 %	348 223 kr
AVANZA BANK HOLDING AB 0.7261 %	11,039,123	0.7261 %	311 303 kr
Teknik Innovation Norden Fonder AB 0.6962 %	10,585,110	0.6962 %	298 500 kr
Håkan Stödberg 0.3481 %	5,292,555	0.3481 %	149 250 kr
Martin Åmark 0.1090 %	1,657,469	0.1090 %	46 741 kr
Siavash Bashiri 0.0700 %	1,064,809	0.0700 %	30 028 kr

Xbrane Biopharma AB

Retzius väg 8

171 65, Solna

+46 8 55 90 56 00

http://www.xbrane.com

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.208 SEK

Average target price

0.625 SEK

Spread / Average Target

+200.48%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
XBRANE BIOPHARMA AB	-97.92%	29.78M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research